Novartis receives European Commission approval for self-administration of Xolair® across all indications
- The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe1
- Xolair® (omalizumab) prefilled syringe (PFS) is the first and only biologic to receive European Commission (EC) approval for self-administration in severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU)
- Novartis is reimagining care in SAA and CSU by providing patients the flexibility to fit their treatment around their lives
Basel, Switzerland, December 13, 2018 – Novartis today announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment. With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU.
Xolair, which targets immunoglobulin E (IgE), is the first and only biologic to be approved in the European Union, Iceland, Norway, and Liechtenstein for self-administration (or administration by a trained caregiver) for the treatment of SAA in patients 6 years of age and older that have difficulty in controlling their asthma symptoms and for CSU in patients 12 years of age and older who continue to have hives that are not controlled by H1 antihistamines. Studies in severe allergic asthma and chronic spontaneous urticaria have shown that appropriately trained patients can effectively self-administer Xolair at home1-3.
The efficacy of Xolair has been demonstrated in large-scale clinical trials and real world studies. Xolair has been shown to reduce severe exacerbations and corticosteroid use in SAA1, as well as rapidly reduce symptoms in CSU4.
The EC approval will allow patients with no known history of anaphylaxis to self-inject Xolair PFS, or be injected by a trained lay-caregiver, from the fourth dose onwards, if a physician determines that this is appropriate5. The patient or the caregiver must have been trained in the correct sub-cutaneous injection technique and the recognition of the early signs and symptoms of serious allergic reactions5.
“Today’s positive news is a big step forward for patients living with immunoglobulin E- mediated asthma and chronic spontaneous urticaria. Decreasing the number of regular clinic visits allows patients the flexibility to fit their treatment around their lives and helps to reduce the burden of these diseases. It also allows physicians a greater capacity for patients who need extra care, which is important” said Professor Dr. Karl-Christian Bergmann, Allergy Center Charité, Berlin.
Administered via injection every two or four weeks, Xolair is widely used and well tolerated6. With 13 years of physician experience in Europe and one million patient years of exposure, use of Xolair in SAA and CSU is supported by a wealth of evidence from randomized clinical trials and real-world studies1-3. Anaphylactic reactions were rare in clinical trials (≥ 1/10,000 to < 1/1,000)5 and via post-marketing reports (approximately 0.2 percent)5.
About Allergic Asthma and Chronic Spontaneous Urticaria
Asthma is a serious and chronic lung disease affecting an estimated 235 million people around the world7. It causes swelling and narrowing of the airways, making breathing difficult7. Allergic asthma, the most common form of asthma, accounts for approximately 60 percent of asthma cases8,9.
Urticaria is a severe disease characterized by persistent hives and/or painful deeper swelling of the skin tissue (angioedema). When this persists for 6 weeks or more, it is classified as chronic urticaria10. Chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria (CIU), is identified as the appearance of hives and/or angioedema without an identifiable trigger for more than 6 weeks10. Most patients with CSU remain symptomatic for more than one year, but in some patients, symptoms may persist for decades10.
Xolair (omalizumab) is the only approved antibody designed to target and block immunoglobulin E (IgE). By reducing free IgE, down-regulating high-affinity IgE receptors and limiting mast cell degranulation, Xolair minimizes the release of mediators throughout the allergic inflammatory cascade.
As an injectable prescription medicine, Xolair is approved for the treatment of moderate-to-severe or severe persistent allergic asthma in more than 90 countries, including the US since 2003 and the EU since 2005. Xolair is approved for the treatment of CSU in over 80 countries including the European Union and for chronic idiopathic urticaria (CIU), as it is known in the US and Canada. Xolair has over one million patient years of exposure. In addition, a liquid formulation of Xolair in pre-filled syringes has been approved in the EU and more than 10 countries outside of the EU, including Canada, the US, and Australia. In the US, Novartis and Genentech, Inc. work together to develop and co-promote Xolair. Outside the US, Novartis markets Xolair and records all sales and related costs.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact email@example.com
- Liebhaber M and Dyer Z. J Asthma 2007; 44(3): 195-196.
- Ghazanfar M and Thomsen S. J Dermatolog Treat 2018; 29(2): 196.
- Denman S et al. Br J Dermatol 2016; 175(6): 1405-1407.
- Maurer M et al. N Engl J Med 2013; 368(10): 924-935.
- Xolair® Summary of Product Characteristics. Novartis Europharm Limited. Available at: INSERT WHEN AVAILABLE. Last accessed: December 2018.
- Humbert M et al. Allergy 2005; 60(3): 309-316.
- World Health Organization. Asthma. Available at: http://www.who.int/respiratory/asthma/en/. Last Accessed: December 2018.
- American Academy of Allergy, Asthma & Immunology (AAAAI). Allergic Asthma Definition. Available at: http://www.aaaai.org/conditions-and-treatments/conditions-a-to-z-search/allergic-asthma.aspx. Last accessed December 2018.
- Arbes S. et al. Asthma cases attributable to atopy: Results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2007; 120(5): 1139-45.
- Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011; 66(3): 317-330.
# # #
|Novartis Media Relations|
|Central media line: +41 61 324 2200|
|Eric Althoff||Beyza Oezel|
|Novartis Global Media Relations||Global Head, Respiratory Communications|
|+41 61 324 7999 (direct)||+41 61 696 9503 (direct)|
|+41 79 593 4202 (mobile)||+41 79 720 4038 (mobile)|
|Novartis Investor Relations|
|Central investor relations line: +41 61 324 7944|
|Samir Shah +41 61 324 7944||Richard Pulik +1 212 830 2448|
|Pierre-Michel Bringer +41 61 324 1065||Cory Twining +1 212 830 2417|
|Thomas Hungerbuehler +41 61 324 8425|
|Isabella Zinck +41 61 324 7188|